Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown.
Source: MedWire News - Oncology - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva